<?xml version="1.0" encoding="ISO-8859-1"?>
<entity-relation-data lastUpdate="2023-03-27 16:54:02" record="28008" source="Espacenet">
	<entities>
		<entity ref="Patent28008" type="Patent">
			<semanticIdentifier>brcris::d455dc3250a8cc598197d7588c1e1eaf</semanticIdentifier>
			<semanticIdentifier>docdb::BR102014032447A2</semanticIdentifier>
			<semanticIdentifier>epodoc::BR102014032447</semanticIdentifier>
			<semanticIdentifier>docdb::BR102014032447A</semanticIdentifier>
			<semanticIdentifier>epodoc::BR20141032447</semanticIdentifier>
			<semanticIdentifier>original::102014032447</semanticIdentifier>
			<field name="urlEspacenet" value="https://worldwide.espacenet.com/patent/search?q=102014032447"/>
			<field name="identifier.lattes" value="6858139747014559"/>
			<field name="identifier.espacenet" value="102014032447"/>
			<field name="kindCode" value="A2"/>
			<field name="title.espacenet" value="composições antileishmania contendo o fulerol e uso"/>
			<field name="title.lattes" value="Composições Antileishmania Contendo o Fulerol e Uso"/>
			<field name="depositDate" value="2014-12-23"/>
			<field name="publicationDate" value="2016-09-27"/>
			<field name="countryCode" value="BR"/>
			<field name="inventor" value="FREDERIC JEAN GEORGES FREZARD"/>
			<field name="inventor" value="GUILHERME SANTOS RAMOS"/>
			<field name="inventor" value="KELLY CRISTINA KATO"/>
			<field name="inventor" value="LUIZ ORLANDO LADEIRA"/>
			<field name="inventor" value="MARIA NORMA MELO"/>
			<field name="inventor" value="MARINA DE SOUZA LADEIRA"/>
			<field name="inventor" value="MAURICIO VELOSO BRANT PINHEIRO"/>
			<field name="inventor" value="PAULA PEIXOTO CAMPOS"/>
			<field name="inventor" value="PRISCILA GOMES DOS REIS"/>
			<field name="inventor" value="RICARDO TOSHIO FUJIWARA"/>
			<field name="inventor" value="SILVIA CAROLINA GUATIMOSIM FONSECA"/>
			<field name="applicant" value="UNIVERSIDADE FEDERAL DE MINAS GERAIS"/>
			<field name="classification.ipc">
				<field name="sequence" value="1"/>
				<field name="text" value="A61K9/00AI"/>
				<field name="section" value="A"/>
				<field name="class" value="61"/>
				<field name="subclass" value="K"/>
				<field name="group" value="9"/>
				<field name="subgroup" value="00AI"/>
			</field>
			<field name="classification.ipc">
				<field name="sequence" value="2"/>
				<field name="text" value="A61K31/045AI"/>
				<field name="section" value="A"/>
				<field name="class" value="61"/>
				<field name="subclass" value="K"/>
				<field name="group" value="31"/>
				<field name="subgroup" value="045AI"/>
			</field>
			<field name="classification.ipc">
				<field name="sequence" value="3"/>
				<field name="text" value="A61K47/00AI"/>
				<field name="section" value="A"/>
				<field name="class" value="61"/>
				<field name="subclass" value="K"/>
				<field name="group" value="47"/>
				<field name="subgroup" value="00AI"/>
			</field>
			<field name="classification.ipc">
				<field name="sequence" value="4"/>
				<field name="text" value="A61P33/02AI"/>
				<field name="section" value="A"/>
				<field name="class" value="61"/>
				<field name="subclass" value="P"/>
				<field name="group" value="33"/>
				<field name="subgroup" value="02AI"/>
			</field>
			<field name="abstract.espacenet" value="composições antileishmania contendo o fulerol e uso. a presente invenção refere-se às composições farmacêuticas contendo fulerenos, preferencialmente o fulerol, que são nanoestruturas esféricas de carbono, como novas ferramentas para o tratamento das leishmanioses visceral e cutânea. as composições antileishmania contendo o fulerol podem compreender ainda um outro fármaco leishmanicida ou imunomodulador, estando na forma livre ou associada a um nanocarreador, tal como lipossomas, que confere propriedades farmacocinéticas mais favoráveis aos princípios ativos. o fulerol demonstrou de forma surpreendente uma atividade antileishmania, assim como uma capacidade de reduzir a hepatotoxicidade do antimoniato de meglumina quando administrado em associação em modelo animal de leishmaniose visceral. desta forma, o fulerol apresentou-se como o primeiro fármaco a demonstrar a dupla capacidade de exercer ação antileishmania sem efeitos colaterais e de reduzir a toxicidade de outro fármaco leishmanicida sem interferir na sua atividade farmacológica. por fim, a invenção compreende o uso de composições farmacêuticas contendo fulerenos para o tratamento das leishmanioses."/>
			<field name="originatesFrom" value="57003191"/>
			<field name="alternateIdentifier">
				<field name="status" value="Publication"/>
				<field name="format" value="docdb"/>
				<field name="country" value="BR"/>
				<field name="number" value="102014032447"/>
				<field name="kind" value="A2"/>
			</field>
			<field name="alternateIdentifier">
				<field name="status" value="Publication"/>
				<field name="format" value="epodoc"/>
				<field name="country" value="BR"/>
				<field name="number" value="BR102014032447"/>
				<field name="kind" value=""/>
			</field>
			<field name="alternateIdentifier">
				<field name="status" value="Application"/>
				<field name="format" value="docdb"/>
				<field name="country" value="BR"/>
				<field name="number" value="102014032447"/>
				<field name="kind" value="A"/>
			</field>
			<field name="alternateIdentifier">
				<field name="status" value="Application"/>
				<field name="format" value="epodoc"/>
				<field name="country" value="BR"/>
				<field name="number" value="BR20141032447"/>
				<field name="kind" value=""/>
			</field>
			<field name="alternateIdentifier">
				<field name="status" value="Application"/>
				<field name="format" value="original"/>
				<field name="country" value=""/>
				<field name="number" value="102014032447"/>
				<field name="kind" value=""/>
			</field>
			<field name="urlEspacenet" value="https://worldwide.espacenet.com/patent/search?q=BR102013033866"/>
			<field name="urlEspacenet" value="https://worldwide.espacenet.com/patent/search?q=WO2015101918"/>
		</entity>
		<entity ref="Person19323" type="Person">
			<semanticIdentifier>lattes::6858139747014559</semanticIdentifier>
			<field name="identifier.lattes" value="6858139747014559"/>
			<field name="name" value="Luiz Orlando Ladeira"/>
		</entity>
		<entity ref="OrgUnit15040" type="OrgUnit">
			<semanticIdentifier>brcris::b325025cd443a1ebf025d67185ebad24</semanticIdentifier>
			<field name="name" value="UNIVERSIDADE FEDERAL DE MINAS GERAIS"/>
		</entity>
		<entity ref="Patent28009" type="Patent">
			<semanticIdentifier>epodoc::BR102013033866</semanticIdentifier>
			<field name="countryCode" value="BR"/>
			<field name="originatesFrom" value="57003191"/>
			<field name="alternateIdentifier">
				<field name="status" value="Publication"/>
				<field name="format" value="epodoc"/>
				<field name="country" value="BR"/>
				<field name="number" value="BR102013033866"/>
				<field name="kind" value=""/>
			</field>
		</entity>
		<entity ref="Patent28010" type="Patent">
			<semanticIdentifier>epodoc::WO2015101918</semanticIdentifier>
			<field name="countryCode" value="WO"/>
			<field name="originatesFrom" value="57003191"/>
			<field name="alternateIdentifier">
				<field name="status" value="Publication"/>
				<field name="format" value="epodoc"/>
				<field name="country" value="WO"/>
				<field name="number" value="WO2015101918"/>
				<field name="kind" value=""/>
			</field>
		</entity>
	</entities>
	<relations>
		<relation fromEntityRef="Patent28008" toEntityRef="Person19323" type="Inventor"/>
		<relation fromEntityRef="Patent28008" toEntityRef="OrgUnit15040" type="Applicant"/>
	</relations>
</entity-relation-data>
